The Pharmacogenetic and Pathological Assessment of CYP2C19 Activity in Patients with Advanced Cancer

The Pharmacogenetic and Pathological Assessment of CYP2C19 Activity in Patients with Advanced Cancer as determined by omeprazole metabolism

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000393651

Acronym

CYP2C19

Enrollment

Registered

2005-09-14

Start date

2005-08-29

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Omeprazole

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with advanced cancer who last received cytotoxic or hormonal therapy for their cancer more than four weeks ago and who are being considered for a new line of therapy for disease progression or inadequate response to prior therapy; adequate renal and liver function; Patients must be able to provide informed consent

Exclusion criteria

Patients receiving medication which is either a CYP2C19 inhibitor or inducer.

Outcome results